Clinical Need
Mitral Regurgitation (MR) is the most common valvular heart disorder in the United States, occurring in about 1.7% of the general population and more than 9% of those over the age of 75.1 Polares Medical is focused on treating Functional Mitral Regurgitation (FMR), the most prevalent form of MR.
A large gap in available treatment for FMR
5 Million
in the US
The current estimated prevalence of moderate and severe MR in the United States is 2 to 2.5 million, and it is expected that this number will rise to 5 million by 2030.²
60K
per year
US MR patients treated with available therapies.
Current Treatments
- Medical Therapy — limited efficacy
- Surgical repair or replacement — high risk
- Transcatheter repair or replacement — anatomical limitations
Publication References
- Journal of the American Heart Association. 2022;11:e022908. DOI: 10.1161/JAHA.121.022908
- Nkomo V, Gardin J, Skelton T et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-11.
A novel approach to fill the space between transcatheter Mitral Valve Repair and Replacement.